Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration resistant prostate cancer
Authors
Xie, W.Ravi, P.
Buyse, M.
Halabi, S.
Kantoff, P.
Sartor, O.
Soule, H.
Clarke, Noel
Dignam, J.
James, N.
Fizazi, K.
Gillessen, S.
Mottet, N.
Murphy, L.
Parulekar, W.
Sandler, H.
Tombal, B.
Williams, S.
Sweeney, C. J.
Affiliation
The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2023
Metadata
Show full item recordAbstract
BACKGROUND: Prior work from the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) consortium (ICECaP-1) demonstrated that metastasis-free survival (MFS) is a valid surrogate for overall survival (OS) in localized prostate cancer (PCa). This was based on data from patients treated predominantly before 2004, prior to docetaxel being available for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). We sought to validate surrogacy in a more contemporary era (ICECaP-2) with greater availability of docetaxel and other systemic therapies for mCRPC. PATIENTS & METHODS: Eligible trials for ICECaP-2 were those providing individual patient data (IPD) after publication of ICECaP-1 and evaluating adjuvant/salvage therapy for localized PCa, and which collected MFS and OS data. MFS was defined as distant metastases or death from any cause, and OS defined as death from any cause. Surrogacy was evaluated using a meta-analytic two-stage validation model, with an R(2) ≥0.7 defined a priori as clinically relevant. RESULTS: 15,164 IPD from 14 trials were included in ICECaP-2, with 70% of patients treated after 2004. Median follow-up was 8.3 years and median post-metastasis survival was 3.1 years in ICECaP-2, compared to 1.9 years in ICECaP-1. For surrogacy condition 1, Kendall's tau was 0.92 for MFS with OS at the patient-level, and R(2) from weighted linear regression (WLR) of 8-yr OS on 5-yr MFS was 0.73 (95% CI 0.53-0.82) at the trial level. For condition 2, R(2) was 0.83 (0.64-0.89) from WLR of log(HR)-OS on log(HR)-MFS. The surrogate threshold effect on OS was an HR(MFS) of 0.81. CONCLUSION: MFS remained a valid surrogate for OS in a more contemporary era, where patients had greater access to docetaxel and other systemic therapies for mCRPC. This supports the use of MFS as the primary outcome measure for ongoing adjuvant trials in localized PCa.Citation
Xie W, Ravi P, Buyse M, Halabi S, Kantoff P, Sartor O, et al. VALIDATION OF METASTASIS-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN LOCALIZED PROSTATE CANCER IN THE ERA OF DOCETAXEL FOR CASTRATION RESISTANT PROSTATE CANCER. Annals of oncology : official journal of the European Society for Medical Oncology. 2023 Dec 5. PubMed PMID: 38061427. Epub 2023/12/08. eng.Journal
Annals of OncologyDOI
10.1016/j.annonc.2023.11.017PubMed ID
38061427Additional Links
https://dx.doi.org/10.1016/j.annonc.2023.11.017Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2023.11.017
Scopus Count
Collections
Related articles
- Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
- Authors: Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ, ICECaP Working Group
- Issue date: 2020 Sep 10
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
- Authors: Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ, ICECaP Working Group
- Issue date: 2017 Sep 20
- Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
- Authors: Jackson WC, Tang M, Schipper MJ, Sandler HM, Zumsteg ZS, Efstathiou JA, Shipley WU, Seiferheld W, Lukka HR, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Hall WA, Dess RT, Lovett RD, Balogh AG, Feng FY, Spratt DE
- Issue date: 2022 Sep 20
- Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
- Authors: Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MD
- Issue date: 2014 Dec
- Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
- Authors: Mahon KL, Qu W, Lin HM, Spielman C, Cain D, Jacobs C, Stockler MR, Higano CS, de Bono JS, Chi KN, Clark SJ, Horvath LG
- Issue date: 2019 Sep